---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-068817"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2024-06-06T23:59:59+00:00"
generated_at: "2026-06-01T05:51:11.392423+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sagimet reports positive FASCINATE-2 Phase 2b data; denifanstat meets primary endpoints in MASH

## Summary
- Primary endpoint: MASH resolution with ≥2-point NAS reduction without worsening fibrosis: 38% denifanstat vs 16% placebo (p=0.0035) in ITT.
- Fibrosis improvement ≥1 stage without worsening MASH: 30% vs 14% placebo (p=0.0199) in ITT; 49% vs 13% in F3 subgroup (p=0.0032).
- Fibrosis improvement ≥2 stages in mITT: 20% vs 2% placebo (p=0.0065); 34% vs 4% in F3 subgroup (p=0.0050).
- No treatment-related SAEs; most AEs mild/moderate. TEAE discontinuation 19.6% denifanstat vs 5.4% placebo.
- Company plans to initiate Phase 3 registrational program for denifanstat in MASH with fibrosis in H2 2024.

## SEC filing metadata
- accession: 0001104659-24-068817
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2024-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465924068817/0001104659-24-068817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465924068817/tm2416614d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-068817
- JSON: https://secwatch.observer/filing/0001104659-24-068817.json
- Plain text: https://secwatch.observer/filing/0001104659-24-068817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.